Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M

CORCEPT THERAPEUTICS INC

2023-Q2 EPS reported $0.38 revenue$223,369,000

Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.
Raises FY 2023 revenue guidance to $455-470M from $435-455M; cash $363.3M.
Repurchased 6.6M shares for $145.4M in April 2023.
Clinical: GRACE Phase 3 enrollment complete; relacorilant NDA submission expected Q2 2024.
ROSELLA ovarian cancer trial enrollment on track to complete by end of 2023; Phase 2b NASH trial to start Q4 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CORCEPT THERAPEUTICS INC reported the quarter ended June 30, 2023 results: revenue $117.7 million, net income $27.5 million, EPS $0.25 (diluted). Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $117.7 million
Net income: $27.5 million
EPS: $0.25 (diluted)
Guidance: raised
Result: reported results

Exact text from the filing

metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results • Revenue of $117.7 million, a 14 percent increase from second quarter 2022 • Increase in 2023 revenue guidance to $455 – $470 million, from $435 – $455 million • Net income per common share of $0.25

View on SEC.gov

Browse all earnings releases →

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001628280-23-026757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.